Identifying the optimal dose of cannabidiol by intrabuccal administration in Kramnik (C3HeB/FeJ) mice

Abstract

Background: Cannabidiol (CBD) has numerous therapeutic properties, and is used to treat neurological conditions, such as neuroinflammation. However, the optimal dose of CBD to penetrate the brain requires further investigation. The primary aim of this study was to use a mouse model and the intrabuccal route for CBD administration to determine the optimal dose at which CBD can penetrate the brain. The secondary aim was to determine whether sex is a confounding factor.

Methods: Thirty adult Kramnik mice, divided equally into three groups, were administered CBD oil intrabuccally at three doses—10, 20, and 30 mg/kg, euthanized 6 h later, and whole brain, urine, and blood samples were collected. Liquid chromatography with tandem mass spectrometry was used to analyze the collected samples.

Results: CBD and its three metabolites—7-carboxy cannabidiol (7-COOH-CBD), 7-hydroxy cannabidiol (7-OH-CBD) and 6-hydroxy cannabidiol (6-OH-CBD), were identified and quantified in all samples. The 10 and 20 mg/kg doses of CBD produced similar results in the brain, but the group given the 10 mg/kg dose had the least variation. The 30 mg/kg dose yielded the highest abundance of CBD and its metabolites in all samples, but also the greatest variation. Sex only became a confounding factor at 30 mg/kg.

Conclusions: This study shows that the intrabuccal route of CBD administration is reliable and the 10 mg/kg dose of CBD is recommended in mice because there were good CBD metabolite concentrations in all samples, with the least variation among the doses, and sex was not a confounder at 10 mg/kg.

Keywords

brain / C3HeB/FeJ mice / cannabidiol (CBD) / dosage / intrabuccal administration / LC–MS/MS

References

[1] Stasiłowicz A, Tomala A, Podolak I, Cielecka-Piontek J. Cannabis sativa L. as a natural drug meeting the criteria of a multitarget approach to treatment. Int J Mol Sci. 2021; 2: 778.

[2] Liu Y, Xiao A-P, Cheng H, et al. Phytochemical differences of hemp (Cannabis sativa L.) leaves from different germplasms and their regulatory effects on lipopolysaccharide-induced inflammation in Matin-Darby canine kidney cell lines. Front Nutr. 2022; 9: 902625.

[3] Flores-Sanchez IJ, Verpoorte R. Secondary metabolism in cannabis. Phytochem Rev. 2008; 7: 615-639.

[4] Pénzes Z, Alimohammadi S, Horváth D, et al. The dual role of cannabidiol on monocyte-derived dendritic cell differentiation and maturation. Front Immunol. 2023; 14: 1240800.

[5] Chagas MH, Eckeli A, Zuardi AW, et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. J Clin Pharm Ther. 2014; 5: 564-566.

[6] Aziz A-I, Nguyen LC, Oumeslakht L, Bensussan A, Ben MS. Cannabinoids as immune system modulators: cannabidiol potential therapeutic approaches and limitations. Cannabis Cannabinoid Res. 2023; 2: 254-269.

[7] Singh K, Bhushan B, Chanchal DK, et al. Emerging therapeutic potential of cannabidiol (CBD) in neurological disorders: a comprehensive review. Behav Neurol. 2023; 2023: 20-23.

[8] Omotayo OP, Lemmer Y, Mason S. A narrative review of the therapeutic and remedial prospects of cannabidiol with emphasis on neurological and neuropsychiatric disorders. J Cannabis Res. 2024; 1: 14.

[9] Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants. 2019; 1: 21.

[10] Mazzantini C, El Bourji Z, Parisio C, et al. Anti-inflammatory properties of cannabidiol and beta-caryophyllene alone or combined in an in vitro inflammation model. Pharmaceuticals. 2024; 4: 467.

[11] Cabrera CLR, Keir-Rudman S, Horniman N, Clarkson N, Page C. The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination. Pulm Pharmacol Ther. 2021; 69: 102047.

[12] FDA. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. Press Announcement 2018; FDA.

[13] Calapai F, Cardia L, Sorbara EE, et al. Cannabinoids, blood-brain barrier, and brain disposition. Pharmaceuticals. 2020; 3: 265.

[14] Millar SA, Stone NL, Yates AS, O'Sullivan SE. A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018; 9: 1365.

[15] Hložek T, Uttl L, Kadeřábek L, et al. Pharmacokinetic and behavioural profile of THC, CBD, and THC + CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC. Eur Neuropsychopharmacol. 2017; 12: 1223-1237.

[16] Deiana S, Watanabe A, Yamasaki Y, et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology. 2012; 219: 859-873.

[17] Sallam NA, Peterson CS, Baglot SL, et al. Sex differences in plasma, adipose tissue, and central accumulation of cannabinoids, and behavioral effects of oral cannabis consumption in male and female C57BL/6 mice. Int J Neuropsychopharmacol. 2023; 11: 773-783.

[18] Koyi PK, Khan AB. Buccal patches: a review. Int J Pharm Sci Res. 2013; 1: 83-89.

[19] Nair VV, Cabrera P, Ramírez-Lecaros C, Jara MO, Brayden DJ, Morales JO. Buccal delivery of small molecules and biologics: of mucoadhesive polymers, films, and nanoparticles-an update. Int J Pharm. 2023; 636: 122789.

[20] Schwotzer D, Kulpa J, Trexler K, et al. Pharmacokinetics of cannabidiol in Sprague-Dawley rats after oral and pulmonary administration. Cannabis Cannabinoid Res. 2023; 2: 360-373.

[21] Terburgh K, Coetzer J, Lindeque JZ, van der Westhuizen FH, Louw R. Aberrant BCAA and glutamate metabolism linked to regional neurodegeneration in a mouse model of Leigh syndrome. Biochim Biophys Acta. 2021; 5: 166082.

[22] Patel JG, Solanki SS, Patel KB, Patel MP, Patel JK. Buccal drug delivery system: a review. Res J Pharm Technol. 2012; 7: 883-888.

[23] Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018; 32: 1053-1067.

[24] Briânis RC, Iglesias LP, Bedeschi LG, Moreira FA. Effects of cannabidiol on reward contextual memories induced by cocaine in male and female mice. Acta Neuropsychiatr. 2023; 36: 1-8.

[25] Rock EM, Limebeer CL, Smoum R, Mechoulam R, Parker LA. Evaluation of sex differences in the potential of Δ9-tetrahydrocannabinol, cannabidiol, cannabidiolic acid, and oleoyl alanine to reduce nausea-induced conditioned gaping reactions in Sprague-Dawley rats. Cannabic Cannabinoid Res. 2023; 6: 1060-1068.

[26] Craft RM, Gogulski HY, Freels TG, Glodosky NC, McLaughlin RJ. Vaporized cannabis extract-induced antinociception in male vs female rats with persistent inflammatory pain. Pain. 2023; 9: 2036-2047.

[27] Pigliasco F, Malaca S, Lo Faro AF, et al. Cannabidiol,∆ 9-tetrahydrocannabinol, and metabolites in human blood by volumetric absorptive microsampling and LC-MS/MS following controlled administration in epilepsy patients. Front Pharmacol. 2022; 13: 1038754.

[28] Turner SE, Knych HK, Adams AA. Pharmacokinetics of cannabidiol in a randomized crossover trial in senior horses. Am J Vet Res. 2022; 83: 9.

[29] Chicoine A, Illing K, Vuong S, Pinto KR, Alcorn J, Cosford K. Pharmacokinetic and safety evaluation of various oral doses of a novel 1:20 THC:CBD cannabis herbal extract in dogs. Front Vet Sci. 2020; 7: 583404.

[30] Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood-brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther. 2023; 1: 217.

[31] Pérez-Acevedo AP, Busardò FP, Pacifici R, et al. Disposition of cannabidiol metabolites in serum and urine from healthy individuals treated with pharmaceutical preparations of medical cannabis. Pharmaceuticals. 2020; 12: 459.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.